QHSLab (USAQ) reports 57% April revenue jump and launches PAN sales network
Rhea-AI Filing Summary
QHSLab, Inc. shared a shareholder update highlighting strong recent operating trends and growth initiatives. Unaudited revenue for April 2026 was approximately $325,889, up from $207,538 in April 2025, representing about 57% year-over-year growth, driven by increasing use of its digital medicine platform and integrated service program.
The Company introduced the QHS Practice Access Network (PAN), a nationwide independent representative program intended to accelerate adoption of its Q-Connect platform by leveraging existing healthcare relationships for warm introductions to physician practices. QHSLab also plans to present at the 2026 Planet MicroCap Showcase on June 16–18, 2026, to expand investor awareness of its digital health strategy.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
Regulation FD Disclosure regulatory
QHS Practice Access Network (PAN) financial
digital medicine platform financial
integrated service program (ISP) financial
recurring service fees financial
forward-looking statements regulatory
FAQ
How did QHSLab (USAQ) perform in April 2026 revenue?
What is QHSLab’s QHS Practice Access Network (PAN)?
How does QHSLab (USAQ) generate most of its revenue?
What is QHSLab’s core business focus in digital health?
What upcoming investor event will QHSLab (USAQ) attend?
How is QHSLab (USAQ) seeking to expand market adoption of Q-Connect?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported):
(Exact Name of Registrant as Specified in its Charter)
(Commission File No.)
(State of Incorporation) |
(I.R.S. Employer Identification No.) | |
| (Address of Principal Executive Offices) | (ZIP Code) |
Registrant’s
telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) |
Securities registered pursuant to Section 12(g) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On May 26, 2026, QHSLab, Inc. (the “Company”), issued a shareholder update regarding certain recent operational developments, including:
(i) unaudited April 2026 revenue results,
(ii) the Company’s development of the QHS Practice Access Network (PAN), a relationship-driven independent representative initiative designed to support growth of the Company’s Q-Connect platform, and
(iii) the Company’s planned participation in the 2026 Planet MicroCap Showcase conference June 16-18, 2026.
A copy of the shareholder update is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information furnished pursuant to Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits.
The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.
| Exhibit No. | Description | |
| 99.1 | Letter to shareholders dated May 26, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: May 26, 2026 | ||
| QHSLab, Inc. | ||
| /s/ Troy Grogan | ||
| Name: | Troy Grogan | |
| Title: | CEO and Chairman | |
Exhibit 99.1
QHSLAB, INC. (OTCQB: USAQ)
Shareholder Update – May 26, 2026
Dear Shareholders,
As we continue building QHSLab, a scalable digital healthcare infrastructure company for primary care practices, we wanted to provide shareholders with updates regarding several recent important operational and strategic business performance, market expansion initiatives, and upcoming investor visibility opportunities.
April 2026 Unaudited Revenue Update
QHSLab is pleased to report that unaudited revenue for April 2026 was approximately $325,889, compared to $207,538 during the same period in 2025, representing year-over-year growth of approximately 57%.
This continued growth reflects increasing utilization of the Company’s digital medicine platform, ongoing expansion of the integrated service program (ISP), and continued demand from physician practices seeking operationally integrated patient engagement and reimbursement solutions.
The Company remains focused on expanding recurring revenue opportunities through practice activation, improved assessment completion rates, and broader adoption of Q-Connect within primary care environments.
Introduction of the QHS Practice Access Network (PAN)
QHSLab is also introducing a new growth initiative developed internally which is now market ready known as the QHS Practice Access Network (PAN), a nationwide independent representative initiative designed to accelerate adoption of the Company’s Q-Connect platform.
The program is built around a relationship-driven market access strategy that leverages highly connected healthcare professionals, consultants, and medical industry representatives who already maintain trusted relationships with physician owners, practice administrators, and healthcare decision-makers.
Unlike traditional cold-call sales models, the PAN initiative is designed to create warm introductions into qualified practices, reduce customer acquisition friction, improve onboarding efficiency, and accelerate operational activation of new accounts.
Management believes healthcare adoption continues to be heavily influenced by trust, reputation, and existing professional relationships, particularly within independent and regional primary care groups. By utilizing independent representatives who already possess deep physician relationships and operational familiarity, the Company believes it can significantly improve the pace and efficiency of new practice opportunities entering the QHSLab pipeline.
The PAN initiative is intended to complement the Company’s internal sales and implementation teams by focusing resources on pre-qualified opportunities while simultaneously expanding national market reach.
Planet MicroCap Conference June 16-18, 2026
QHSLab is pleased to announce that the Company will be presenting at the 2026 Planet MicroCap Showcase, one of the leading conferences focused on connecting emerging growth public companies with institutional and retail investors.
Participation in the Planet MicroCap conference provides an important opportunity to increase investor awareness, expand visibility within the microcap investment community, and communicate the Company’s evolving digital health growth strategy to new potential shareholders and strategic market participants.
The event brings together public company executives, investors, analysts, and industry participants focused on identifying emerging growth opportunities across multiple sectors, including healthcare technology and digital health.
As QHSLab continues executing its growth initiatives, management remains focused on expanding operational scale, increasing recurring revenue opportunities, strengthening physician adoption, and building long-term shareholder value.
We appreciate the continued support of our shareholders and look forward to providing additional updates in the coming months.
Sincerely,
Troy Grogan
President & Chief Executive Officer
About QHSLab
QHSLab, Inc. (OTCQB: USAQ) is a scalable digital health infrastructure company supporting independent primary care practices through workflow-integrated digital screening, clinical decision support, and care management services. The Company’s platform is designed to help physicians identify and manage underdiagnosed behavioral health and chronic conditions while supporting reimbursable clinical activities that occur both during and outside traditional office visits. QHSLab generates revenue primarily through recurring service fees from participating medical practices. The Company also operates an allergy diagnostics and treatment service line under the AllergiEnd® brand. Learn more at www.qhslab.com
Forward-Looking Statements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investor Relations Contact:
Olivia Giamanco
QHSLab, Inc.
(929) 379-6503
ir@usaqcorp.com
https://twitter.com/QHSLabInc